| Pharmaceutical Information |
| Drug Name |
Talazoparib |
| Drug ID |
BADD_D02485 |
| Description |
Talazoparib was approved by the FDA for use in germline BRCA mutated, HER2 negative, locally advanced or metastatic breast cancer on October 16, 2018 under the trade name Talzenna [L4661]. Talzenna was granted approval based on the results of the EMBRACA trial in which talazoparib resulted in a mean 8.6 months progression-free survival time versus physician's choice chemotherapy which resulted in 5.6 months progression-free survival. |
| Indications and Usage |
Talazoparib is indicated for the treatment of deleterious or suspected deleterious germline BRCA mutated, HER2 negative locally advanced or metastatic breast cancer in adults [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XK04 |
| DrugBank ID |
DB11760
|
| KEGG ID |
D10732
|
| MeSH ID |
C586365
|
| PubChem ID |
135565082
|
| TTD Drug ID |
D0GV8J
|
| NDC Product Code |
46014-0350; 0069-1195; 0069-1235; 0069-1031; 63539-051; 63539-295; 46014-3130; 0069-1751; 46014-1140; 46014-0370; 46014-0360; 46014-3120; 0069-1501; 0069-0296 |
| UNII |
9QHX048FRV
|
| Synonyms |
talazoparib | Talzenna | BMN 673 | BMN-673 | BMN673 |
|
| Chemical Information |
| Molecular Formula |
C19H14F2N6O |
| CAS Registry Number |
1207456-01-6 |
| SMILES |
CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
